Effects of Oral Semaglutide on Urinary Albumin to Creatinine Ratio in Patients with Type 2 Diabetes

Abstract

　Background: Oral semaglutide has been shown to be particularly effective for a range of goals, including reducing HbA1c and weight. No studies have investigated its effects on the urinary albumin to creatinine ratio (UACR), however. This study investigated the effects of switching to oral semaglutide from dipeptidyl peptidase-4 (DPP4) inhibitors on UACR in patients with type 2 diabetes.

　Methods: Thirty patients with type 2 diabetes (15 men, 15 women; average age, 60.3 years) whose UACR was measured before and after switching from DPP4 inhibitors to oral semaglutide were investigated. The effects were compared between before and after 6.6 months on average body weight, systolic and diastolic blood pressure, HbA1c, low-density lipoprotein cholesterol (LDL-C), and UACR.

　Results: After switching from a DPP4 inhibitor to oral semaglutide, HbA1c decreased significantly (8.3 ± 1.1％ before switching, 7.4 ± 0.9％ after switching, p＜0.001). Body weight (71.8 ± 13.7 kg before switching, 68.4 ± 12.6 kg after switching, p＜0.001), systolic blood pressure (140.4 ± 17.0 mmHg before switching, 135.4 ± 13.8 mmHg after switching, p＜0.01), LDL-C (111.1 ± 20.4 mg/dL before switching, 98.8 ± 21.5 mg/dL after switching, p＜0.01), and UACR (194.2±311.8 mg/g･Cre before switching, 121.2 ± 224.3 mg/g･Cre after switching, p＜0.001) also significantly decreased.

　Conclusion: Switching from DPP4 inhibitors to oral semaglutide resulted in reductions in HbA1c, body weight, systolic blood pressure, LDL-C, and UACR in patients with type 2 diabetes.